Terminated PHASE1 INTERVENTIONAL NCT00080028

Motexafin Gadolinium With Chemotherapy and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer

Phase I Trial of Motexafin Gadolinium and Chemoradiation in Locally Advanced, Squamous Cell Carcinoma of the Head and Neck

Sponsor: Pharmacyclics LLC.

Conditions Head and Neck Cancer Hypopharynx Cancer Larynx Cancer Oropharynx Cancer

Interventions Motexafin Gadolinium Injection

Updated 5 times since 2017 Last updated: May 4, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This trial was terminated. No reason was provided.

Other terminated trials from Pharmacyclics LLC.

More terminations from Pharmacyclics LLC.

Other Head and Neck Cancer trials with similar outcome

Browse all Head and Neck Cancer trials

This PHASE1 trial investigates Head and Neck Cancer and Hypopharynx Cancer and is currently terminated or withdrawn. Pharmacyclics LLC. leads this study, which shows 5 recorded versions since 2026 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE1
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE1
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE1
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE1
Jan 2017 — Jun 2018 [monthly]

Terminated PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pharmacyclics LLC.

Data source: Pharmacyclics LLC.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Durham, United States
• San Antonio, United States